Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2015

Open Access 01-12-2015 | Case report

A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch Syndrome

Author: Steven Sorscher

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2015

Login to get access

Abstract

Patients with Lynch Syndrome are at high risk for developing a variety of cancers including cancers of the colon or rectum, small bowel, stomach, uterus, renal pelvis, ureter, biliary tract, ovaries, brain and pancreas (N Engl J Med 348: 919-32, 2003; Gut 57:1097-101, 2008; NCCN, Inc Guideline. Ft. Washington, PA. Online Version 2.2014). Lack of MLH-1 and MSH-2 expression commonly result from germline mutations in this inherited cancer syndrome. Here, we report the case of a patient with a molecularly confirmed germline mutation in MLH-1 along with a colon cancer showing lack of expression of MLH-1 as well as a squamous cell cancer of the skin from the abdominal wall also demonstrating lack of expression of MLH-1. This case appears to represent the second case report of a squamous cell skin cancer apparently due to the Lynch Syndrome and further supports a proposed relationship between Lynch Syndrome and these tumors.
Literature
1.
go back to reference Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 2003, 348: 919–32. 10.1056/NEJMra012242CrossRefPubMed Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 2003, 348: 919–32. 10.1056/NEJMra012242CrossRefPubMed
2.
go back to reference Koeller T, Oestergaard MZ, Song H, Tyrer J, Perkins B, Dunning AM, et al.: Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008, 57: 1097. 10.1136/gut.2007.137265CrossRef Koeller T, Oestergaard MZ, Song H, Tyrer J, Perkins B, Dunning AM, et al.: Common variants in mismatch repair genes and risk of colorectal cancer. Gut 2008, 57: 1097. 10.1136/gut.2007.137265CrossRef
3.
go back to reference Provenzate D, Jasperson K, Ahnen D, Aslanian H, Bray T, Cannon JA, et al.: Genetic/familial high risk assessment: colorectal. National Comprehensive Cancer Network, Inc version 2, Ft. Washington; 2014. Provenzate D, Jasperson K, Ahnen D, Aslanian H, Bray T, Cannon JA, et al.: Genetic/familial high risk assessment: colorectal. National Comprehensive Cancer Network, Inc version 2, Ft. Washington; 2014.
4.
go back to reference Gray SE, Kay EW, Leader M, Mabruk M: Enhanced detection of microsatellite instability and mismatch repair gene expression in cutaneous squamous cell carcinomas. Mol Diag Ther 2006, 10: 327–334. 10.1007/BF03256208CrossRef Gray SE, Kay EW, Leader M, Mabruk M: Enhanced detection of microsatellite instability and mismatch repair gene expression in cutaneous squamous cell carcinomas. Mol Diag Ther 2006, 10: 327–334. 10.1007/BF03256208CrossRef
5.
go back to reference Mathiak MI, Rutten A, Mangold E, Fischer HP, Ruzicka T, Friedl W, et al.: Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH-2 or MLH-1 germline mutations: establishment as a screening test. Am J Surg Pathol 2002, 26: 338–43. 10.1097/00000478-200203000-00007CrossRefPubMed Mathiak MI, Rutten A, Mangold E, Fischer HP, Ruzicka T, Friedl W, et al.: Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH-2 or MLH-1 germline mutations: establishment as a screening test. Am J Surg Pathol 2002, 26: 338–43. 10.1097/00000478-200203000-00007CrossRefPubMed
Metadata
Title
A case of squamous cell carcinoma of the skin due to the molecularly confirmed Lynch Syndrome
Author
Steven Sorscher
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2015
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-015-0033-2

Other articles of this Issue 1/2015

Hereditary Cancer in Clinical Practice 1/2015 Go to the issue

Letter to the Editor

PARP inhibitors

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine